VCYT
HealthcareVeracyte, Inc.
$32.06+1.13 (+3.65%)
Prev Close
$30.93
Open
$31.26
High
$32.28
Low
$31.06
Volume
849.8K
Market Cap
$2.64B
P/E
39.10
Div Yield
—
Over the past 12 months, insider activity at Veracyte, Inc. (VCYT) has been exclusively selling, with 0 insider purchases totaling $0.00 and 42 insider sales totaling $14.39M. The most recent insider transaction was by Chambers Rebecca (officer: Chief Financial Officer), who sold $662.9K worth of shares on Mar 6, 2026. Veracyte, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.64B.
Buys (12M)
0
$0.00
Sells (12M)
42
$14.39M
Net Activity
Net Seller
$14.39M
Active Insiders
11
last 12 mo
VCYT Price Chart
VCYT Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 6, 2026↗ | Chambers Rebecca | officer: Chief Financial Officer | Sell | 18,341 | $36.14 | $662.9K | 145,137 |
| Mar 6, 2026↗ | Leite John | officer: Chief Commercial Officer-CLIA | Sell | 5,260 | $35.19 | $185.1K | 107,580 |
| Mar 6, 2026↗ | McGuire Annie | officer: SVP, General Counsel | Sell | 6,658 | $35.55 | $236.7K | 96,370 |
| Mar 6, 2026↗ | Stapley Marc | director, officer: Chief Executive Officer | Sell | 45,523 | $35.97 | $1.64M | 383,833 |
| Mar 4, 2026↗ | Febbo Phillip G. | officer: Chief Scientific & Med Officer | Sell | 26,850 | $36.16 | $970.9K | 117,346 |
| Dec 16, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 10,739 | $43.13 | $463.2K | 0 |
| Dec 5, 2025↗ | EASTHAM KARIN | Director | Sell | 20,000 | $45.45 | $908.9K | 0 |
| Dec 2, 2025↗ | Chambers Rebecca | Chief Financial Officer | Sell | 16,662 | $46.70 | $778.2K | 0 |
| Dec 2, 2025↗ | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 2,955 | $46.16 | $136.4K | 0 |
| Dec 2, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 4,178 | $46.57 | $194.6K | 0 |
| Dec 2, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 4,474 | $46.52 | $208.1K | 0 |
| Dec 2, 2025↗ | Stapley Marc | Chief Executive Officer | Sell | 15,582 | $46.62 | $726.4K | 0 |
| Dec 2, 2025↗ | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 1,325 | $46.16 | $61.2K | 0 |
| Nov 25, 2025↗ | JONES EVAN/ FA | Director | Sell | 1,106 | $50.25 | $55.6K | 0 |
| Nov 25, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 2,808 | $50.00 | $140.4K | 0 |
| Nov 20, 2025↗ | Holstein Jens | Director | Sell | 10,000 | $42.36 | $423.6K | 0 |
| Nov 7, 2025↗ | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 10,920 | $41.20 | $449.9K | 0 |
| Nov 5, 2025↗ | Chambers Rebecca | Chief Financial Officer | Sell | 7,000 | $41.00 | $287.0K | 0 |
| Nov 5, 2025↗ | EASTHAM KARIN | Director | Sell | 9,674 | $40.02 | $387.2K | 0 |
| Nov 5, 2025↗ | JONES EVAN/ FA | Director | Sell | 43,196 | $45.06 | $1.95M | 0 |
| Nov 5, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 6,466 | $40.00 | $258.6K | 0 |
| Oct 6, 2025↗ | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 8,349 | $36.02 | $300.7K | 0 |
| Oct 1, 2025↗ | EPSTEIN ROBERT S | Director | Sell | 21,473 | $35.08 | $753.2K | 0 |
| Oct 1, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 2,539 | $35.00 | $88.9K | 0 |
| Oct 1, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 2,160 | $35.00 | $75.6K | 0 |
| Sep 19, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 2,283 | $33.69 | $76.9K | 0 |
| Sep 4, 2025↗ | Stapley Marc | Chief Executive Officer | Sell | 7,667 | $30.41 | $233.1K | 0 |
| Sep 2, 2025↗ | Chambers Rebecca | Chief Financial Officer | Sell | 5,371 | $30.11 | $161.7K | 0 |
| Sep 2, 2025↗ | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 2,955 | $30.11 | $89.0K | 0 |
| Sep 2, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 2,902 | $30.11 | $87.4K | 0 |
| Sep 2, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 3,507 | $30.11 | $105.6K | 0 |
| Sep 2, 2025↗ | Stapley Marc | Chief Executive Officer | Sell | 7,914 | $30.11 | $238.3K | 0 |
| Sep 2, 2025↗ | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 1,648 | $30.11 | $49.6K | 0 |
| Jun 13, 2025↗ | Bhanji Muna | Director | Sell | 4,589 | $26.67 | $122.4K | 0 |
| Jun 13, 2025↗ | EASTHAM KARIN | Director | Sell | 4,590 | $26.66 | $122.4K | 0 |
| Jun 4, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 2,809 | $27.20 | $76.4K | 0 |
| Jun 2, 2025↗ | Chambers Rebecca | Chief Financial Officer | Sell | 5,370 | $26.74 | $143.6K | 0 |
| Jun 2, 2025↗ | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 2,955 | $26.74 | $79.0K | 0 |
| Jun 2, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 2,900 | $26.74 | $77.5K | 0 |
| Jun 2, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 3,505 | $26.74 | $93.7K | 0 |
| Jun 2, 2025↗ | Stapley Marc | Chief Executive Officer | Sell | 9,399 | $26.74 | $251.3K | 0 |
| Jun 2, 2025↗ | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 1,848 | $26.74 | $49.4K | 0 |
| Mar 6, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 7,411 | $31.66 | $234.6K | 0 |
| Mar 4, 2025↗ | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 8,037 | $33.35 | $268.0K | 0 |
| Mar 4, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 1,142 | $33.69 | $38.5K | 0 |
| Mar 4, 2025↗ | Stapley Marc | Chief Executive Officer | Sell | 52,697 | $33.34 | $1.76M | 0 |
| Mar 2, 2025↗ | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 4,301 | $34.76 | $149.5K | 0 |
| Feb 27, 2025↗ | Chambers Rebecca | Chief Financial Officer | Sell | 22,981 | $34.28 | $787.9K | 0 |
| Feb 27, 2025↗ | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 22,426 | $34.12 | $765.1K | 0 |
| Feb 27, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 13,396 | $34.37 | $460.4K | 0 |
| Feb 27, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 15,255 | $34.34 | $523.8K | 0 |
| Feb 27, 2025↗ | Stapley Marc | Chief Executive Officer | Sell | 54,597 | $34.18 | $1.87M | 0 |
VCYT Insider Buying Activity
The following table shows recent insider purchases of Veracyte, Inc. (VCYT) stock reported via SEC Form 4 filings.
No insider buying activity found for VCYT in the last 12 months.
VCYT Insider Selling Activity
The following table shows recent insider sales of Veracyte, Inc. (VCYT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 6, 2026↗ | Chambers Rebecca | officer: Chief Financial Officer | Sell | 18,341 | $36.14 | $662.9K | 145,137 |
| Mar 6, 2026↗ | Leite John | officer: Chief Commercial Officer-CLIA | Sell | 5,260 | $35.19 | $185.1K | 107,580 |
| Mar 6, 2026↗ | McGuire Annie | officer: SVP, General Counsel | Sell | 6,658 | $35.55 | $236.7K | 96,370 |
| Mar 6, 2026↗ | Stapley Marc | director, officer: Chief Executive Officer | Sell | 45,523 | $35.97 | $1.64M | 383,833 |
| Mar 4, 2026↗ | Febbo Phillip G. | officer: Chief Scientific & Med Officer | Sell | 26,850 | $36.16 | $970.9K | 117,346 |
| Dec 16, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 10,739 | $43.13 | $463.2K | 0 |
| Dec 5, 2025↗ | EASTHAM KARIN | Director | Sell | 20,000 | $45.45 | $908.9K | 0 |
| Dec 2, 2025↗ | Chambers Rebecca | Chief Financial Officer | Sell | 16,662 | $46.70 | $778.2K | 0 |
| Dec 2, 2025↗ | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 2,955 | $46.16 | $136.4K | 0 |
| Dec 2, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 4,178 | $46.57 | $194.6K | 0 |
| Dec 2, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 4,474 | $46.52 | $208.1K | 0 |
| Dec 2, 2025↗ | Stapley Marc | Chief Executive Officer | Sell | 15,582 | $46.62 | $726.4K | 0 |
| Dec 2, 2025↗ | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 1,325 | $46.16 | $61.2K | 0 |
| Nov 25, 2025↗ | JONES EVAN/ FA | Director | Sell | 1,106 | $50.25 | $55.6K | 0 |
| Nov 25, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 2,808 | $50.00 | $140.4K | 0 |
| Nov 20, 2025↗ | Holstein Jens | Director | Sell | 10,000 | $42.36 | $423.6K | 0 |
| Nov 7, 2025↗ | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 10,920 | $41.20 | $449.9K | 0 |
| Nov 5, 2025↗ | Chambers Rebecca | Chief Financial Officer | Sell | 7,000 | $41.00 | $287.0K | 0 |
| Nov 5, 2025↗ | EASTHAM KARIN | Director | Sell | 9,674 | $40.02 | $387.2K | 0 |
| Nov 5, 2025↗ | JONES EVAN/ FA | Director | Sell | 43,196 | $45.06 | $1.95M | 0 |
| Nov 5, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 6,466 | $40.00 | $258.6K | 0 |
| Oct 6, 2025↗ | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 8,349 | $36.02 | $300.7K | 0 |
| Oct 1, 2025↗ | EPSTEIN ROBERT S | Director | Sell | 21,473 | $35.08 | $753.2K | 0 |
| Oct 1, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 2,539 | $35.00 | $88.9K | 0 |
| Oct 1, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 2,160 | $35.00 | $75.6K | 0 |
| Sep 19, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 2,283 | $33.69 | $76.9K | 0 |
| Sep 4, 2025↗ | Stapley Marc | Chief Executive Officer | Sell | 7,667 | $30.41 | $233.1K | 0 |
| Sep 2, 2025↗ | Chambers Rebecca | Chief Financial Officer | Sell | 5,371 | $30.11 | $161.7K | 0 |
| Sep 2, 2025↗ | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 2,955 | $30.11 | $89.0K | 0 |
| Sep 2, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 2,902 | $30.11 | $87.4K | 0 |
| Sep 2, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 3,507 | $30.11 | $105.6K | 0 |
| Sep 2, 2025↗ | Stapley Marc | Chief Executive Officer | Sell | 7,914 | $30.11 | $238.3K | 0 |
| Sep 2, 2025↗ | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 1,648 | $30.11 | $49.6K | 0 |
| Jun 13, 2025↗ | Bhanji Muna | Director | Sell | 4,589 | $26.67 | $122.4K | 0 |
| Jun 13, 2025↗ | EASTHAM KARIN | Director | Sell | 4,590 | $26.66 | $122.4K | 0 |
| Jun 4, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 2,809 | $27.20 | $76.4K | 0 |
| Jun 2, 2025↗ | Chambers Rebecca | Chief Financial Officer | Sell | 5,370 | $26.74 | $143.6K | 0 |
| Jun 2, 2025↗ | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 2,955 | $26.74 | $79.0K | 0 |
| Jun 2, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 2,900 | $26.74 | $77.5K | 0 |
| Jun 2, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 3,505 | $26.74 | $93.7K | 0 |
| Jun 2, 2025↗ | Stapley Marc | Chief Executive Officer | Sell | 9,399 | $26.74 | $251.3K | 0 |
| Jun 2, 2025↗ | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 1,848 | $26.74 | $49.4K | 0 |
| Mar 6, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 7,411 | $31.66 | $234.6K | 0 |
| Mar 4, 2025↗ | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 8,037 | $33.35 | $268.0K | 0 |
| Mar 4, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 1,142 | $33.69 | $38.5K | 0 |
| Mar 4, 2025↗ | Stapley Marc | Chief Executive Officer | Sell | 52,697 | $33.34 | $1.76M | 0 |
| Mar 2, 2025↗ | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 4,301 | $34.76 | $149.5K | 0 |
| Feb 27, 2025↗ | Chambers Rebecca | Chief Financial Officer | Sell | 22,981 | $34.28 | $787.9K | 0 |
| Feb 27, 2025↗ | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 22,426 | $34.12 | $765.1K | 0 |
| Feb 27, 2025↗ | Leite John | Chief Commercial Officer-CLIA | Sell | 13,396 | $34.37 | $460.4K | 0 |
| Feb 27, 2025↗ | McGuire Annie | SVP, General Counsel | Sell | 15,255 | $34.34 | $523.8K | 0 |
| Feb 27, 2025↗ | Stapley Marc | Chief Executive Officer | Sell | 54,597 | $34.18 | $1.87M | 0 |
VCYT Insiders
Similar Stocks to VCYT
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B